# Allison Transmission Holdings Inc: financial statements, quarterly

ALSN · NYSE · CIK 1411207 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alsn.md) · [Financials](/companies/alsn/financials.md) · [Filings](/companies/alsn/filings.md) · [Insiders](/companies/alsn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alsn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [736](/filings/0000950170-24-118639.md) | [775 d](/filings/0001193125-26-065627.md) | [789](/filings/0000950170-25-062281.md) | [816](/filings/0000950170-25-103020.md) | [824](/filings/0001193125-25-257624.md) | [796 d](/filings/0001193125-26-065627.md) | [766](/filings/0001193125-26-211857.md) | [814](/filings/0001193125-26-334039.md) | [693](/filings/0001193125-25-257624.md) | [737 d](/filings/0001193125-26-065627.md) | [1,406](/filings/0001193125-26-211857.md) | [1,566](/filings/0001193125-26-334039.md) |
| Cost of revenue | $m | [379](/filings/0000950170-24-118639.md) | [404 d](/filings/0001193125-26-065627.md) | [423](/filings/0000950170-25-062281.md) | [422](/filings/0000950170-25-103020.md) | [428](/filings/0001193125-25-257624.md) | [423 d](/filings/0001193125-26-065627.md) | [388](/filings/0001193125-26-211857.md) | [411](/filings/0001193125-26-334039.md) | [364](/filings/0001193125-25-257624.md) | [383 d](/filings/0001193125-26-065627.md) | [1,000](/filings/0001193125-26-211857.md) | [1,051](/filings/0001193125-26-334039.md) |
| Gross profit | $m | [357](/filings/0000950170-24-118639.md) | [371 d](/filings/0001193125-26-065627.md) | [366](/filings/0000950170-25-062281.md) | [394](/filings/0000950170-25-103020.md) | [396](/filings/0001193125-25-257624.md) | [373 d](/filings/0001193125-26-065627.md) | [378](/filings/0001193125-26-211857.md) | [403](/filings/0001193125-26-334039.md) | [329](/filings/0001193125-25-257624.md) | [354 d](/filings/0001193125-26-065627.md) | [406](/filings/0001193125-26-211857.md) | [515](/filings/0001193125-26-334039.md) |
| Research and development | $m | [49.0](/filings/0000950170-24-118639.md) | [54.0 d](/filings/0001193125-26-065627.md) | [46.0](/filings/0000950170-25-062281.md) | [49.0](/filings/0000950170-25-103020.md) | [51.0](/filings/0001193125-25-257624.md) | [54.0 d](/filings/0001193125-26-065627.md) | [42.0](/filings/0001193125-26-211857.md) | [43.0](/filings/0001193125-26-334039.md) | [43.0](/filings/0001193125-25-257624.md) | [44.0 d](/filings/0001193125-26-065627.md) | [54.0](/filings/0001193125-26-211857.md) | [56.0](/filings/0001193125-26-334039.md) |
| Selling, general and administrative | $m | [86.0](/filings/0000950170-24-118639.md) | [92.0 d](/filings/0001193125-26-065627.md) | [86.0](/filings/0000950170-25-062281.md) | [82.0](/filings/0000950170-25-103020.md) | [85.0](/filings/0001193125-25-257624.md) | [83.0 d](/filings/0001193125-26-065627.md) | [87.0](/filings/0001193125-26-211857.md) | [104](/filings/0001193125-26-334039.md) | [82.0](/filings/0001193125-25-257624.md) | [110 d](/filings/0001193125-26-065627.md) | [157](/filings/0001193125-26-211857.md) | [168](/filings/0001193125-26-334039.md) |
| Operating income | $m | [222](/filings/0000950170-24-118639.md) | [225 d](/filings/0001193125-26-065627.md) | [234](/filings/0000950170-25-062281.md) | [263](/filings/0000950170-25-103020.md) | [260](/filings/0001193125-25-257624.md) | [235 d](/filings/0001193125-26-065627.md) | [249](/filings/0001193125-26-211857.md) | [256](/filings/0001193125-26-334039.md) | [204](/filings/0001193125-25-257624.md) | [171 d](/filings/0001193125-26-065627.md) | [195](/filings/0001193125-26-211857.md) | [291](/filings/0001193125-26-334039.md) |
| Income tax | $m | [35.0](/filings/0000950170-24-118639.md) | [36.0 d](/filings/0001193125-26-065627.md) | [35.0](/filings/0000950170-25-062281.md) | [47.0](/filings/0000950170-25-103020.md) | [49.0](/filings/0001193125-25-257624.md) | [35.0 d](/filings/0001193125-26-065627.md) | [41.0](/filings/0001193125-26-211857.md) | [47.0](/filings/0001193125-26-334039.md) | [45.0](/filings/0001193125-25-257624.md) | [48.0 d](/filings/0001193125-26-065627.md) | [20.0](/filings/0001193125-26-211857.md) | [47.0](/filings/0001193125-26-334039.md) |
| Net income | $m | [158](/filings/0000950170-24-118639.md) | [170 d](/filings/0001193125-26-065627.md) | [169](/filings/0000950170-25-062281.md) | [187](/filings/0000950170-25-103020.md) | [200](/filings/0001193125-25-257624.md) | [175 d](/filings/0001193125-26-065627.md) | [192](/filings/0001193125-26-211857.md) | [195](/filings/0001193125-26-334039.md) | [137](/filings/0001193125-25-257624.md) | [99.0 d](/filings/0001193125-26-065627.md) | [112](/filings/0001193125-26-211857.md) | [181](/filings/0001193125-26-334039.md) |
| Diluted EPS | $ per share | [1.76](/filings/0000950170-24-118639.md) | not reported | [1.90](/filings/0000950170-25-062281.md) | [2.13](/filings/0000950170-25-103020.md) | [2.27](/filings/0001193125-25-257624.md) | not reported | [2.23](/filings/0001193125-26-211857.md) | [2.29](/filings/0001193125-26-334039.md) | [1.63](/filings/0001193125-25-257624.md) | not reported | [1.33](/filings/0001193125-26-211857.md) | [2.15](/filings/0001193125-26-334039.md) |
| Basic EPS | $ per share | [1.76](/filings/0000950170-24-118639.md) | not reported | [1.92](/filings/0000950170-25-062281.md) | [2.15](/filings/0000950170-25-103020.md) | [2.30](/filings/0001193125-25-257624.md) | not reported | [2.26](/filings/0001193125-26-211857.md) | [2.32](/filings/0001193125-26-334039.md) | [1.63](/filings/0001193125-25-257624.md) | not reported | [1.35](/filings/0001193125-26-211857.md) | [2.18](/filings/0001193125-26-334039.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [501](/filings/0000950170-23-055372.md) | [555](/filings/0000950170-25-019379.md) | [551](/filings/0000950170-24-048677.md) | [648](/filings/0000950170-24-086738.md) | [788](/filings/0000950170-24-118639.md) | [781](/filings/0001193125-26-065627.md) | [753](/filings/0000950170-25-062281.md) | [778](/filings/0000950170-25-103020.md) | [902](/filings/0001193125-25-257624.md) | [1,495](/filings/0001193125-26-334039.md) | [311](/filings/0001193125-26-211857.md) | [399](/filings/0001193125-26-334039.md) |
| Current assets | $m | [1,217](/filings/0000950170-23-055372.md) | [1,250](/filings/0000950170-25-019379.md) | [1,300](/filings/0000950170-24-048677.md) | [1,423](/filings/0000950170-24-086738.md) | [1,592](/filings/0000950170-24-118639.md) | [1,538](/filings/0001193125-26-065627.md) | [1,565](/filings/0000950170-25-062281.md) | [1,587](/filings/0000950170-25-103020.md) | [1,671](/filings/0001193125-25-257624.md) | [2,233](/filings/0001193125-26-334039.md) | [2,302](/filings/0001193125-26-211857.md) | [2,389](/filings/0001193125-26-334039.md) |
| Total assets | $m | [4,987](/filings/0000950170-23-055372.md) | [5,025](/filings/0001193125-26-065627.md) | [5,056](/filings/0000950170-25-062281.md) | [5,176](/filings/0000950170-25-103020.md) | [5,368](/filings/0001193125-25-257624.md) | [5,336](/filings/0001193125-26-065627.md) | [5,366](/filings/0000950170-25-062281.md) | [5,411](/filings/0000950170-25-103020.md) | [5,517](/filings/0001193125-25-257624.md) | [6,082](/filings/0001193125-26-334039.md) | [8,703](/filings/0001193125-26-211857.md) | [8,717](/filings/0001193125-26-334039.md) |
| Current liabilities | $m | [504](/filings/0000950170-23-055372.md) | [501](/filings/0000950170-25-019379.md) | [518](/filings/0000950170-24-048677.md) | [511](/filings/0000950170-24-086738.md) | [563](/filings/0000950170-24-118639.md) | [506](/filings/0001193125-26-065627.md) | [513](/filings/0000950170-25-062281.md) | [472](/filings/0000950170-25-103020.md) | [438](/filings/0001193125-25-257624.md) | [460](/filings/0001193125-26-334039.md) | [1,247](/filings/0001193125-26-211857.md) | [1,322](/filings/0001193125-26-334039.md) |
| Total liabilities | $m | [3,803](/filings/0000950170-23-055372.md) | [3,792](/filings/0000950170-25-019379.md) | [3,714](/filings/0000950170-24-048677.md) | [3,692](/filings/0000950170-24-086738.md) | [3,747](/filings/0000950170-24-118639.md) | [3,685](/filings/0001193125-26-065627.md) | [3,701](/filings/0000950170-25-062281.md) | [3,658](/filings/0000950170-25-103020.md) | [3,676](/filings/0001193125-25-257624.md) | [4,215](/filings/0001193125-26-334039.md) | [6,800](/filings/0001193125-26-211857.md) | [6,738](/filings/0001193125-26-334039.md) |
| Long-term debt | $m | [2,498](/filings/0000950170-23-055372.md) | [2,497](/filings/0000950170-25-019379.md) | [2,398](/filings/0000950170-24-048677.md) | [2,397](/filings/0000950170-24-086738.md) | [2,396](/filings/0000950170-24-118639.md) | [2,395](/filings/0001193125-26-065627.md) | [2,395](/filings/0000950170-25-062281.md) | [2,394](/filings/0000950170-25-103020.md) | [2,393](/filings/0001193125-25-257624.md) | [2,885](/filings/0001193125-26-334039.md) | [4,247](/filings/0001193125-26-211857.md) | [4,094](/filings/0001193125-26-334039.md) |
| Current portion of debt | $m | [6.0](/filings/0000950170-23-055372.md) | [6.0](/filings/0000950170-25-019379.md) | [5.0](/filings/0000950170-24-048677.md) | [5.0](/filings/0000950170-24-086738.md) | [5.0](/filings/0000950170-24-118639.md) | [5.0](/filings/0001193125-26-065627.md) | [5.0](/filings/0000950170-25-062281.md) | [5.0](/filings/0000950170-25-103020.md) | [5.0](/filings/0001193125-25-257624.md) | [5.0](/filings/0001193125-26-065627.md) | not reported | not reported |
| Shareholders' equity | $m | [1,184](/filings/0000950170-24-118639.md) | [1,233](/filings/0001193125-26-065627.md) | [1,342](/filings/0000950170-25-103020.md) | [1,484](/filings/0001193125-25-257624.md) | [1,621](/filings/0001193125-25-257624.md) | [1,651](/filings/0001193125-26-334039.md) | [1,665](/filings/0001193125-26-334039.md) | [1,753](/filings/0001193125-26-334039.md) | [1,841](/filings/0001193125-25-257624.md) | [1,867](/filings/0001193125-26-334039.md) | [1,903](/filings/0001193125-26-334039.md) | [1,979](/filings/0001193125-26-334039.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [212 d](/filings/0000950170-24-118639.md) | [238 d](/filings/0001193125-26-065627.md) | [173](/filings/0000950170-25-062281.md) | [171 d](/filings/0000950170-25-103020.md) | [246 d](/filings/0001193125-25-257624.md) | [211 d](/filings/0001193125-26-065627.md) | [181](/filings/0001193125-26-211857.md) | [184 d](/filings/0001193125-26-334039.md) | [228 d](/filings/0001193125-25-257624.md) | [243 d](/filings/0001193125-26-065627.md) | [156](/filings/0001193125-26-211857.md) | [312 d](/filings/0001193125-26-334039.md) |
| Capital expenditure | $m | [30.0 d](/filings/0000950170-24-118639.md) | [52.0 d](/filings/0001193125-26-065627.md) | [11.0](/filings/0000950170-25-062281.md) | [21.0 d](/filings/0000950170-25-103020.md) | [36.0 d](/filings/0001193125-25-257624.md) | [75.0 d](/filings/0001193125-26-065627.md) | [26.0](/filings/0001193125-26-211857.md) | [31.0 d](/filings/0001193125-26-334039.md) | [44.0 d](/filings/0001193125-25-257624.md) | [74.0 d](/filings/0001193125-26-065627.md) | [53.0](/filings/0001193125-26-211857.md) | [31.0 d](/filings/0001193125-26-334039.md) |
| Dividends paid | $m | [20.0 d](/filings/0000950170-24-118639.md) | [20.0 d](/filings/0001193125-26-065627.md) | [22.0](/filings/0000950170-25-062281.md) | [22.0 d](/filings/0000950170-25-103020.md) | [22.0 d](/filings/0001193125-25-257624.md) | [21.0 d](/filings/0001193125-26-065627.md) | [24.0](/filings/0001193125-26-211857.md) | [22.0 d](/filings/0001193125-26-334039.md) | [23.0 d](/filings/0001193125-25-257624.md) | [22.0 d](/filings/0001193125-26-065627.md) | [25.0](/filings/0001193125-26-211857.md) | [24.0 d](/filings/0001193125-26-334039.md) |
| Share repurchases | $m | [20.0 d](/filings/0000950170-24-118639.md) | [106 d](/filings/0001193125-26-065627.md) | [52.0](/filings/0000950170-25-062281.md) | [31.0 d](/filings/0000950170-25-103020.md) | [50.0 d](/filings/0001193125-25-257624.md) | [121 d](/filings/0001193125-26-065627.md) | [150](/filings/0001193125-26-211857.md) | [105 d](/filings/0001193125-26-334039.md) | [27.0 d](/filings/0001193125-25-257624.md) | [46.0 d](/filings/0001193125-26-065627.md) | [20.0](/filings/0001193125-26-211857.md) | [46.0 d](/filings/0001193125-26-334039.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [96.0](/filings/0000950170-23-055372.md) | [92.0](/filings/0000950170-24-048677.md) | [91.0](/filings/0000950170-24-086738.md) | [90.0](/filings/0000950170-24-118639.md) | [89.0](/filings/0000950170-25-062281.md) | [88.0](/filings/0000950170-25-103020.md) | [88.0](/filings/0001193125-25-257624.md) | [86.0](/filings/0001193125-26-211857.md) | [85.0](/filings/0001193125-26-334039.md) | [84.0](/filings/0001193125-25-257624.md) | [84.0](/filings/0001193125-26-211857.md) | [84.0](/filings/0001193125-26-334039.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 82,578,038 at 2026-07-22, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-334039.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.